Cargando…
Selective Inhibition of Liver Cancer Cells Using Venom Peptide
Increasingly cancer is being viewed as a channelopathy because the passage of ions via ion channels and transporters mediate the regulation of tumor cell survival, death, and motility. As a result, a potential targeted therapy for cancer is to use venom peptides that are selective for ion channels a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835663/ https://www.ncbi.nlm.nih.gov/pubmed/31627357 http://dx.doi.org/10.3390/md17100587 |
_version_ | 1783466725678776320 |
---|---|
author | Anand, Prachi Filipenko, Petr Huaman, Jeannette Lyudmer, Michael Hossain, Marouf Santamaria, Carolina Huang, Kelly Ogunwobi, Olorunseun O. Holford, Mandë |
author_facet | Anand, Prachi Filipenko, Petr Huaman, Jeannette Lyudmer, Michael Hossain, Marouf Santamaria, Carolina Huang, Kelly Ogunwobi, Olorunseun O. Holford, Mandë |
author_sort | Anand, Prachi |
collection | PubMed |
description | Increasingly cancer is being viewed as a channelopathy because the passage of ions via ion channels and transporters mediate the regulation of tumor cell survival, death, and motility. As a result, a potential targeted therapy for cancer is to use venom peptides that are selective for ion channels and transporters overexpressed in tumor cells. Here we describe the selectivity and mechanism of action of terebrid snail venom peptide, Tv1, for treating the most common type of liver cancer, hepatocellular carcinoma (HCC). Tv1 inhibited the proliferation of murine HCC cells and significantly reduced tumor size in Tv1-treated syngeneic tumor-bearing mice. Tv1’s mechanism of action involves binding to overexpressed transient receptor potential (TRP) channels leading to calcium dependent apoptosis resulting from down-regulation of cyclooxygenase-2 (COX-2). Our findings demonstrate the importance of modulating ion channels and the unique potential of venom peptides as tumor specific ligands in the quest for targeted cancer therapies. |
format | Online Article Text |
id | pubmed-6835663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68356632019-11-25 Selective Inhibition of Liver Cancer Cells Using Venom Peptide Anand, Prachi Filipenko, Petr Huaman, Jeannette Lyudmer, Michael Hossain, Marouf Santamaria, Carolina Huang, Kelly Ogunwobi, Olorunseun O. Holford, Mandë Mar Drugs Article Increasingly cancer is being viewed as a channelopathy because the passage of ions via ion channels and transporters mediate the regulation of tumor cell survival, death, and motility. As a result, a potential targeted therapy for cancer is to use venom peptides that are selective for ion channels and transporters overexpressed in tumor cells. Here we describe the selectivity and mechanism of action of terebrid snail venom peptide, Tv1, for treating the most common type of liver cancer, hepatocellular carcinoma (HCC). Tv1 inhibited the proliferation of murine HCC cells and significantly reduced tumor size in Tv1-treated syngeneic tumor-bearing mice. Tv1’s mechanism of action involves binding to overexpressed transient receptor potential (TRP) channels leading to calcium dependent apoptosis resulting from down-regulation of cyclooxygenase-2 (COX-2). Our findings demonstrate the importance of modulating ion channels and the unique potential of venom peptides as tumor specific ligands in the quest for targeted cancer therapies. MDPI 2019-10-17 /pmc/articles/PMC6835663/ /pubmed/31627357 http://dx.doi.org/10.3390/md17100587 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Anand, Prachi Filipenko, Petr Huaman, Jeannette Lyudmer, Michael Hossain, Marouf Santamaria, Carolina Huang, Kelly Ogunwobi, Olorunseun O. Holford, Mandë Selective Inhibition of Liver Cancer Cells Using Venom Peptide |
title | Selective Inhibition of Liver Cancer Cells Using Venom Peptide |
title_full | Selective Inhibition of Liver Cancer Cells Using Venom Peptide |
title_fullStr | Selective Inhibition of Liver Cancer Cells Using Venom Peptide |
title_full_unstemmed | Selective Inhibition of Liver Cancer Cells Using Venom Peptide |
title_short | Selective Inhibition of Liver Cancer Cells Using Venom Peptide |
title_sort | selective inhibition of liver cancer cells using venom peptide |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835663/ https://www.ncbi.nlm.nih.gov/pubmed/31627357 http://dx.doi.org/10.3390/md17100587 |
work_keys_str_mv | AT anandprachi selectiveinhibitionoflivercancercellsusingvenompeptide AT filipenkopetr selectiveinhibitionoflivercancercellsusingvenompeptide AT huamanjeannette selectiveinhibitionoflivercancercellsusingvenompeptide AT lyudmermichael selectiveinhibitionoflivercancercellsusingvenompeptide AT hossainmarouf selectiveinhibitionoflivercancercellsusingvenompeptide AT santamariacarolina selectiveinhibitionoflivercancercellsusingvenompeptide AT huangkelly selectiveinhibitionoflivercancercellsusingvenompeptide AT ogunwobiolorunseuno selectiveinhibitionoflivercancercellsusingvenompeptide AT holfordmande selectiveinhibitionoflivercancercellsusingvenompeptide |